Last reviewed · How we verify

NCT03116568

Bacterial Transmission In Utero and IBD Risk

Active, enrolled Last updated 8 February 2023
What this trial tests

trial in IBD in 180 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline
24 April 2017
Primary endpoint
14 April 2025
27 September 2027

Quick facts

Lead sponsorChinese University of Hong Kong
StatusActive, enrolled
Study typeOBSERVATIONAL
Enrollment180
Start date24 April 2017
Primary completion14 April 2025
Estimated completion27 September 2027
Sites1 location across Hong Kong

Conditions studied

Sponsor

Chinese University of Hong Kong

Who can join

Under 100, any sex, with IBD or Pregnancy Related. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Inflammatory bowel diseases (IBD), Crohn's disease (CD) and ulcerative colitis (UC), are caused by the loss of mucosal tolerance towards the commensal microbiota resulting in inflammatory responses. Identifying intestinal bacteria in mother and newborn of both IBD and Control groups allow us to understand the change of bacterial composition human microbiome in the gut during pregnancy and childhood development.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for IBD

Currently open trials in the same condition.

Other Chinese University of Hong Kong trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03116568.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing